Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04735393 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 757
- Enrollment target
NCT04735393 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 757 participants.
The verdict
NCT04735393, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 757 participants
- Enrollment target
Study Summary
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease
Interventions
- DRUG Placebo Comparator
- DRUG Reproxalap Ophthalmic Solution (0.25%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 757 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04735393
The ClinicalTrials.gov registry entry for NCT04735393 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 757 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT04735393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04735393 about?
NCT04735393 is a clinical study titled "A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease". A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease
What is the current status of trial NCT04735393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 757 participants. The study started on 2021-01-26. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT04735393?
The interventions under investigation include: Placebo Comparator (DRUG), Reproxalap Ophthalmic Solution (0.25%) (DRUG).
Who is sponsoring clinical trial NCT04735393?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.